Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors

HIV Medicine

Volumn 8, Issue 8, 2007, Pages 529-535

  Chetchotisakd, P ^a   Anunnatsiri, S ^a   Mootsikapun, P ^a   Kiertiburanakul, S ^b   Anekthananon, T ^c   Bowonwatanuwong, C ^d   Kowadisaiburana, B ^e   Supparatpinyo, K ^f   Ruxrungtham, K ^g,h  

^a KHON KAEN UNIVERSITY   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

^c MAHIDOL UNIVERSITY   (Thailand)

^d CHONBURI HOSPITAL   (Thailand)

^e Bamrasnaradura Infectious Disease Institute   (Thailand)

^f CHIANG MAI UNIVERSITY   (Thailand)

^g CHULALONGKORN UNIVERSITY   (Thailand)

^h THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

Author keywords

Double boosted protease inhibitor; Nonnucleoside reverse transcriptase inhibitor resistance; Salvage therapy; Thailand

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; DIDANOSINE; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TOXIC HEPATITIS; TREATMENT DURATION; VIRUS LOAD; VOMITING;

ADULT; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; RITONAVIR; RNA, VIRAL; SALVAGE THERAPY; SAQUINAVIR; TREATMENT OUTCOME;

EID: 35448967037     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2007.00506.x     Document Type: Article

References (13)

1. Palella FJ Jr, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-860.
2. Hogg RS, Yip B, Kully C et al. Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens. CMAJ 1999; 160: 659-665.
3. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. DHHS Panel on Clinical Practice for Treatment of HIV infection. October 10, 2006. http://AIDSinfo.nih.gov, (accessed 24 October 2006).
4. Gazzard B on behalf of the BHIVA Writing Committee. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006). HIV Med 2006; 7: 487-503.
5. World Health Organization. Antiretroviral Therapy for HIV Infection in Adults and Adolescents in Resource-Limited Settings: Towards Universal Access: Recommendations for a Public Health Approach; 2006 Revision. Geneva, Switzerland: WHO, 2006.
6. Chetchotisakd P, Anunnatsiri S, Kiertiburanakul S et al. High rate multiple drug resistances in HIV-infected patients failing nonnucleoside reverse transcriptase inhibitor regimens in Thailand, where subtype A/E is predominant. J Int Assoc Physicians AIDS Care (Chic Ill) 2006; 5: 152-156.
7. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B, Chumpathat N, Chantratita W. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. Clin Infect Dis 2007; 44: 447-452.
8. Ananworanich J, Hill A, Siangphoe U et al. A prospective study of efficacy and safety of once-daily saquinavir/ritonavir plus two nucleoside reverse transcriptase inhibitors in treatment-naïve Thai patients. Antivir Ther 2005; 10: 761-767.
9. Lamotte C, Peytavin G, Perre P et al. Increasing adverse events with indinavir dosages and plasma concentrations in four different ritonavir-indinavir containing regimens in HIV-infected patients. VIII Conference on Retroviruses and Opportunistic Infections. Chicago, IL, February 2001 [Abstract 738].
10. Durant J, Clevenbergh P, Garraffo R et al. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: Pharmacological data from the Viradapt Study. AIDS 2000; 14: 1333-1339.
11. Staszewski S, Babacan E, Frankfurt HIV Cohort. et al. The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy. J Antimicrob Chemother 2006; 58: 1024-1030.
12. Deeks SG, Hoh R, Neilands TB et al. Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection. J Infect Dis 2005; 192: 1537-1544.
13. Castagnaa A, Danisea A, Menzoc S et al. Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: A randomized pilot study (E-184V study). AIDS 2006; 20: 795-803.